Petter Bjornstad1, Kimberly L Drews1, Sonia Caprio1, Rose Gubitosi-Klug1, David M Nathan1, Bereket Tesfaldet1, Jeanie Tryggestad1, Neil H White1, Philip Zeitler1. 1. From the University of Colorado Anschutz Medical Campus, Children's Hospital Colorado, Aurora (P.B., P.Z.); George Washington University, Rockville, MD (K.L.D., B.T.); Yale University, New Haven, CT (S.C.); Case Western Reserve University, Rainbow Babies and Children's Hospital, Cleveland (R.G.-K.); the Massachusetts General Hospital Diabetes Center, Harvard Medical School, Boston (D.M.N.); the University of Oklahoma Health Sciences Center, Oklahoma City (J.T.); and Washington University School of Medicine, St. Louis (N.H.W.).
Abstract
BACKGROUND: The prevalence of type 2 diabetes in youth is increasing, but little is known regarding the occurrence of related complications as these youths transition to adulthood. METHODS: We previously conducted a multicenter clinical trial (from 2004 to 2011) to evaluate the effects of one of three treatments (metformin, metformin plus rosiglitazone, or metformin plus an intensive lifestyle intervention) on the time to loss of glycemic control in participants who had onset of type 2 diabetes in youth. After completion of the trial, participants were transitioned to metformin with or without insulin and were enrolled in an observational follow-up study (performed from 2011 to 2020), which was conducted in two phases; the results of this follow-up study are reported here. Assessments for diabetic kidney disease, hypertension, dyslipidemia, and nerve disease were performed annually, and assessments for retinal disease were performed twice. Complications related to diabetes identified outside the study were confirmed and adjudicated. RESULTS: At the end of the second phase of the follow-up study (January 2020), the mean (±SD) age of the 500 participants who were included in the analyses was 26.4±2.8 years, and the mean time since the diagnosis of diabetes was 13.3±1.8 years. The cumulative incidence of hypertension was 67.5%, the incidence of dyslipidemia was 51.6%, the incidence of diabetic kidney disease was 54.8%, and the incidence of nerve disease was 32.4%. The prevalence of retinal disease, including more advanced stages, was 13.7% in the period from 2010 to 2011 and 51.0% in the period from 2017 to 2018. At least one complication occurred in 60.1% of the participants, and at least two complications occurred in 28.4%. Risk factors for the development of complications included minority race or ethnic group, hyperglycemia, hypertension, and dyslipidemia. No adverse events were recorded during follow-up. CONCLUSIONS: Among participants who had onset of type 2 diabetes in youth, the risk of complications, including microvascular complications, increased steadily over time and affected most participants by the time of young adulthood. Complications were more common among participants of minority race and ethnic group and among those with hyperglycemia, hypertension, and dyslipidemia. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; ClinicalTrials.gov numbers, NCT01364350 and NCT02310724.).
BACKGROUND: The prevalence of type 2 diabetes in youth is increasing, but little is known regarding the occurrence of related complications as these youths transition to adulthood. METHODS: We previously conducted a multicenter clinical trial (from 2004 to 2011) to evaluate the effects of one of three treatments (metformin, metformin plus rosiglitazone, or metformin plus an intensive lifestyle intervention) on the time to loss of glycemic control in participants who had onset of type 2 diabetes in youth. After completion of the trial, participants were transitioned to metformin with or without insulin and were enrolled in an observational follow-up study (performed from 2011 to 2020), which was conducted in two phases; the results of this follow-up study are reported here. Assessments for diabetic kidney disease, hypertension, dyslipidemia, and nerve disease were performed annually, and assessments for retinal disease were performed twice. Complications related to diabetes identified outside the study were confirmed and adjudicated. RESULTS: At the end of the second phase of the follow-up study (January 2020), the mean (±SD) age of the 500 participants who were included in the analyses was 26.4±2.8 years, and the mean time since the diagnosis of diabetes was 13.3±1.8 years. The cumulative incidence of hypertension was 67.5%, the incidence of dyslipidemia was 51.6%, the incidence of diabetic kidney disease was 54.8%, and the incidence of nerve disease was 32.4%. The prevalence of retinal disease, including more advanced stages, was 13.7% in the period from 2010 to 2011 and 51.0% in the period from 2017 to 2018. At least one complication occurred in 60.1% of the participants, and at least two complications occurred in 28.4%. Risk factors for the development of complications included minority race or ethnic group, hyperglycemia, hypertension, and dyslipidemia. No adverse events were recorded during follow-up. CONCLUSIONS: Among participants who had onset of type 2 diabetes in youth, the risk of complications, including microvascular complications, increased steadily over time and affected most participants by the time of young adulthood. Complications were more common among participants of minority race and ethnic group and among those with hyperglycemia, hypertension, and dyslipidemia. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; ClinicalTrials.gov numbers, NCT01364350 and NCT02310724.).
Authors: Amanda I Adler; Richard J Stevens; Sue E Manley; Rudy W Bilous; Carole A Cull; Rury R Holman Journal: Kidney Int Date: 2003-01 Impact factor: 10.612
Authors: William V Tamborlane; Margarita Barrientos-Pérez; Udi Fainberg; Helle Frimer-Larsen; Mona Hafez; Paula M Hale; Muhammad Y Jalaludin; Margarita Kovarenko; Ingrid Libman; Jane L Lynch; Paturi Rao; Naim Shehadeh; Serap Turan; Daniel Weghuber; Timothy Barrett Journal: N Engl J Med Date: 2019-04-28 Impact factor: 91.245
Authors: Paula Lozano; Nora B Henrikson; Caitlin C Morrison; John Dunn; Matt Nguyen; Paula R Blasi; Evelyn P Whitlock Journal: JAMA Date: 2016-08-09 Impact factor: 56.272
Authors: Rakesh Amin; Barry Widmer; A Toby Prevost; Phillip Schwarze; Jason Cooper; Julie Edge; Loredana Marcovecchio; Andrew Neil; R Neil Dalton; David B Dunger Journal: BMJ Date: 2008-03-18
Authors: Abdulghani H Al-Saeed; Maria I Constantino; Lynda Molyneaux; Mario D'Souza; Franziska Limacher-Gisler; Connie Luo; Ted Wu; Stephen M Twigg; Dennis K Yue; Jencia Wong Journal: Diabetes Care Date: 2016-03-22 Impact factor: 19.112
Authors: Jedidiah I Morton; Danny Liew; Stephen P McDonald; Jonathan E Shaw; Dianna J Magliano Journal: Diabetes Care Date: 2020-06-15 Impact factor: 19.112
Authors: Kristen J Nadeau; Barbara J Anderson; Erika G Berg; Jane L Chiang; Hubert Chou; Kenneth C Copeland; Tamara S Hannon; Terry T-K Huang; Jane L Lynch; Jeff Powell; Elizabeth Sellers; William V Tamborlane; Philip Zeitler Journal: Diabetes Care Date: 2016-08-02 Impact factor: 19.112
Authors: Paula M Trief; Diane Uschner; Melinda Tung; Marsha D Marcus; Maria Rayas; Sarah MacLeish; Ryan Farrell; Joyce Keady; Lily Chao; Ruth S Weinstock Journal: Diabetes Care Date: 2022-03-01 Impact factor: 19.112
Authors: Helen C Looker; Laura Pyle; Tim Vigers; Cameron Severn; Pierre J Saulnier; Behzad Najafian; Michael Mauer; Robert G Nelson; Petter Bjornstad Journal: Diabetes Care Date: 2022-02-01 Impact factor: 19.112
Authors: Rachana D Shah; Barbara H Braffett; Jeanie B Tryggestad; Kara S Hughan; Ruban Dhaliwal; Kristen J Nadeau; Lorraine E Levitt Katz; Samuel S Gidding Journal: J Diabetes Complications Date: 2022-01-03 Impact factor: 2.852
Authors: EunSeok Cha; Francisco J Pasquel; Fengxia Yan; David R Jacobs; Sandra B Dunbar; Guillermo Umpierrez; Yuni Choi; James M Shikany; Michael P Bancks; Jared P Reis; Melissa Spezia Faulkner Journal: Diabetes Res Clin Pract Date: 2021-11-11 Impact factor: 5.602
Authors: Amy S Shah; Laure El Ghormli; Samuel S Gidding; Kara S Hughan; Lorraine E Levitt Katz; Dorit Koren; Jeanie B Tryggestad; Fida Bacha; Barbara H Braffett; Silva Arslanian; Elaine M Urbina Journal: Acta Diabetol Date: 2021-09-20 Impact factor: 4.280
Authors: Melanie J Davies; Vanita R Aroda; Billy S Collins; Robert A Gabbay; Jennifer Green; Nisa M Maruthur; Sylvia E Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Tsvetalina Tankova; Apostolos Tsapas; John B Buse Journal: Diabetologia Date: 2022-09-24 Impact factor: 10.460
Authors: Amy S Shah; Scott Isom; Ralph D'Agostino; Lawrence M Dolan; Dana Dabelea; Giuseppina Imperatore; Amy Mottl; Eva Lustigova; Catherine Pihoker; Santica Marcovina; Elaine M Urbina Journal: Diabetes Care Date: 2022-07-07 Impact factor: 17.152